

Rene Bruno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7276335/publications.pdf>

Version: 2024-02-01

65
papers

2,708
citations

279701

23
h-index

189801

50
g-index

67
all docs

67
docs citations

67
times ranked

2498
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical pharmacokinetics of bevacizumab in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 779-786.	1.1	317
2	Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 361-369.	1.1	230
3	A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996, 24, 153-172.	0.6	229
4	Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics. <i>Journal of Clinical Oncology</i> , 2009, 27, 4103-4108.	0.8	224
5	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 136-145.	2.3	195
6	Population Pharmacokinetics of Rituximab (Anti-CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 792-801.	1.0	181
7	Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2110-2114.	0.8	119
8	Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. <i>Investigational New Drugs</i> , 2001, 19, 163-169.	1.2	95
9	Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. <i>Clinical Cancer Research</i> , 2003, 9, 1077-82.	3.2	66
10	Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. <i>Statistics in Medicine</i> , 2002, 21, 2623-2639.	0.8	65
11	Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 677-687.	2.3	64
12	Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 518-526.	2.3	60
13	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1257-1267.	1.1	58
14	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. <i>Clinical Cancer Research</i> , 2020, 26, 1787-1795.	3.2	51
15	Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1985, 13, 101-115.	0.6	43
16	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-small Cell Lung Cancer Based on Early Tumor Kinetics. <i>Clinical Cancer Research</i> , 2018, 24, 3292-3298.	3.2	41
17	Evaluation of the linearity of docetaxel pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 155-159.	1.1	39
18	Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 3545-3552.	0.8	36

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 407-414.	1.1	36
20	Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. , 2019, 7, 314.		30
21	Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 653-669.	0.6	28
22	Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1141-1149.	1.1	27
23	Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-up. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 810-820.	2.3	27
24	Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). <i>Clinical and Translational Science</i> , 2022, 15, 130-140.	1.5	27
25	Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2493-2501.	1.1	25
26	Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 917-924.	1.1	24
27	Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1151-1158.	1.1	22
28	A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 6-8.	1.0	22
29	A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain. <i>Pain and Therapy</i> , 2014, 3, 31-44.	1.5	20
30	Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 253-257.	1.0	19
31	Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 567-573.	1.1	19
32	Steady-state dosage regimen calculations in linear pharmacokinetics. <i>International Journal of Bio-medical Computing</i> , 1986, 18, 167-182.	0.5	15
33	Modeling and Simulation of Sexual Activity Daily Diary Data of Patients with Female Sexual Arousal Disorder Treated with Sildenafil Citrate (Viagra®). <i>Pharmaceutical Research</i> , 2006, 23, 1756-1764.	1.7	15
34	Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1171-1182.	1.3	15
35	Application of Machine Learning for Tumor Growth Inhibition Overall Survival Modeling Platform. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 59-66.	1.3	14
36	Time-dependent population PK models of single-agent atezolizumab in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 211-221.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1255-1266.	1.3	13
38	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , 2022, 15, 141-157.	1.5	13
39	Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1385-1390.	0.9	12
40	Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 49-54.	1.1	12
41	Bayesian inference using Hamiltonian Monte Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. <i>Statistics in Medicine</i> , 2020, 39, 4853-4868.	0.8	11
42	Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response. <i>Blood</i> , 2011, 118, 1881-1881.	0.6	11
43	Dynamical dosage regimen calculations in linear pharmacokinetics. <i>Journal of Biomedical Informatics</i> , 1988, 21, 203-220.	0.7	10
44	Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAB) in the Second- and Third-Line Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2017, 19, 527-533.	2.2	10
45	Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 956-958.	2.3	10
46	Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. <i>Anti-Cancer Drugs</i> , 1999, 10, 889-894.	0.7	8
47	Pan-cancer population pharmacokinetics and exposure-safety and efficacy analyses of atezolizumab in patients with high tumor mutational burden. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00685.	1.1	8
48	Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 115-123.	1.3	8
49	Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. <i>Liver Cancer</i> , 2021, 10, 485-499.	4.2	8
50	Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 605-610.	1.1	7
51	Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 613-625.	0.8	7
52	Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation. <i>Journal of Investigative Dermatology</i> , 2021, 141, 930-933.	0.3	6
53	Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1452-1463.	1.1	6
54	Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation. <i>BMC Cancer</i> , 2016, 16, 473.	1.1	5

#	ARTICLE	IF	CITATIONS
55	Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1042-1052.	1.0	5
56	Population pharmacokinetic analysis of etrolizumab in patients with moderately to severely active ulcerative colitis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1244-1255.	1.3	5
57	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab Response. <i>Clinical Cancer Research</i> , 2020, 26, 2436-2436.	3.2	4
58	A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 62-62.	0.8	4
59	Reply to U.R. Mansmann et al and M.-W. An et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 4374-4375.	0.8	3
60	Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1393-1402.	1.0	3
61	Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1065-1066.	0.8	2
62	Model-based estimates of tumor growth inhibition (TGI) metrics to predict for overall survival (OS) in first-line non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e19049-e19049.	0.8	2
63	Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study. <i>AAPS Journal</i> , 2022, 24, 58.	2.2	2
64	Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 225-225.	1.3	0
65	Update to improve reproducibility and interpretability: A response to "Machine Learning for Tumor Growth Inhibition". <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 262-263.	1.3	0